Alerta

COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS

Resumen de: US20260124278A1

0000 Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and/or lipidated GLP-1r agonist analogs with enhanced enzymatic stability needed for gastrointestinal absorption, improved bioavailability and pharmacokinetics are described. In preferred embodiments, the GLP-1r agonist analogs have the amino acid sequence of any one of SEQ ID NOs: 9-35. The compositions are typically administered via oral or parenteral routes. The compositions are particularly suited for treating, alleviating, and/or preventing one or more neurological diseases or disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Methods of treating a human subject having AD or PD or at risk of AD or PD are provided.

METHODS FOR TREATING EARLY ALZHEIMER’S DISEASE

Resumen de: US20260124236A1

Provided herein are methods for treating early Alzheimer's Disease using hydroxypropyl β-cyclodextrin compositions.

Methods and Dosing Regimens for Preventing or Delaying Onset of Alzheimer's Disease and Other Forms of Dementia and Mild Cognitive Impairment

Resumen de: US20260126455A1

0000 Methods and dosing regimens using alpha 7 acetylcholine nicotine receptor binding agents are provided to prevent or inhibit intracellular accumulation of amyloid in cells leading to inhibition or prevention of neuronal cell death. In addition, these methods and dosing regimens are coupled with methods and dosing regimens to reduce and/or prevent blood-brain barrier leakage of vascular-derived amyloid into the brain and/or methods and dosing regimens to reduce and/or prevent neuroinflammation to prevent and/or inhibit the progression of Alzheimer's disease and other forms of dementia and mild cognitive impairment. Also provided are methods for identifying individuals for this treatment.

COMPOUNDS AND METHODS TARGETING INTERLEUKIN-34

Resumen de: US20260125460A1

The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

MODIFIED RELEASE TOLCAPONE FORMULATIONS

Resumen de: US20260124146A1

0000 Modified release tablet dosage forms comprising tolcapone are disclosed. The tablet dosage forms provide a pulsed, pH dependent release profile of tolcapone to both the gastric space and the small intestine. Methods of treating or preventing a disease selected from transthyretin amyloidosis (ATTR), Parkinson's Disease and obsessive compulsive disorder using said dosage forms are provided.

SMALL MOLECULE INHIBITORS OF DYRK1/CLK AND USES THEREOF

Resumen de: WO2026096717A1

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

ANTI-N3PGLU Aβ ANTIBODY AND USE THEREOF

Resumen de: WO2026092407A1

An anti-N3pGlu Aβ antibody, a nucleic acid encoding same and the use thereof. The thermostability and immunogenicity in clinical use of various anti-N3pGlu Aβ antibodies have attracted widespread attention in the development of N3pGlu Aβ antibodies. Clinically, the presence of anti-drug antibodies is correlated to some extent with a shortened half-life thereof. Compared with an antibody without modification, a modified antibody exhibits higher yield and lower immunogenicity, and have better application prospects in the treatment of Alzheimer's disease.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

Resumen de: US20260125364A1

0000 The present invention provides, in part, compounds of Formula I: 0000 0000 and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS

Resumen de: US20260124195A1

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

CRYSTALLINE FORMS OF 6-(6-(((1R,2R,3S,5S)-2-FLUORO-9-AZABICYCLO3.3.1NONAN-3-YL)(METHYL)AMINO)PYRIDAZIN-3-YL)-2-METHYLBENZODOXAZOL-5-OL, A SPLICING MODULATOR FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Resumen de: WO2025006887A1

Described herein are crystalline forms of 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-azabicyclo3.3.1nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzodoxazol-5-ol (compound A), a small molecule splicing modulator (SMSM) of mRNA, such as pre-mRNA, encoded by genes, for the treatment of Huntington's disease.

LEVODOPA-BENSERAZIDE HYDROCHLORIDE COMPOSITION AND PREPARATION THEREFOR

Resumen de: EP4736851A1

0001 Provided in the present invention are a pharmaceutical composition used for treating Parkinson's disease and a preparation method therefor. Tablets prepared from the pharmaceutical composition have better stability, and involve a simple production process, thus facilitating commercial production.

SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF

Resumen de: WO2025006681A2

This application discloses novel substituted pyridazine compounds and analogues, their preparation, pharmaceutical compositions comprising them, and their therapeutic uses as medicaments for treating diseases or disorders associated with modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3, or inhibition of the activation of NLRP3 or related components of the inflammatory process.

COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING DISEASE CAUSED BY PROTEIN NITRATION COMPRISING PEPTIDE WITH TERMINAL TYROSINE AS EFFECTIVE COMPONENT

Resumen de: EP4736869A2

0001 According to the present invention, the peptide with terminal tyrosine has an excellent effect on inhibiting protein nitration and also an excellent effect on preventing, ameliorating, or treating disease symptoms in chronic immobilization stress-induced depression/cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.

Methods and compounds for modulating huntington's disease

Resumen de: WO2025076181A1

The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease (HD).

Methods and compounds for modulating huntington's disease

Resumen de: WO2025076236A1

The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease (HD).

COMPOUNDS

Resumen de: WO2026088070A1

The present invention relates to novel compounds and pharmaceutical compositions. More particularly, the present invention provides novel compounds which are useful for the treatment of and prevention of neurodegenerative disorders including, but not limited to, Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Nasu-Hakola Disease (NHD).

2-(4-PIPERIDYL)-6-(IMIDAZO1,2-BPYRIDAZIN-6-YL)THIENO3,2-BPYRIDINE DERIVATIVES THAT REDUCE THE PROTEIN LEVEL OF HUNTINGTIN (HTT) FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Resumen de: WO2026087399A1

The invention relates to a compound of formula (I) that reduce the protein level of huntingtin (HTT) and which are useful in the treatment of Huntington's disease.

METHODS OF TREATING A NEURODEGENERATIVE DISEASE

Resumen de: WO2026088136A1

The present disclosure provides a method of treating a neurodegenerative disease such as Alzheimer's disease in a subject. The method includes administering to the subject about 30 mg of AR1001 orally once daily, or a pharmaceutically acceptable salt thereof, and monitoring plasma phosphorylated tau 181 (pTau181) or phosphorylated tau 217 (pTau217) levels in the subject during treatment. The method may further include continuing AR1001 treatment if the subject's plasma pTau181 or pTau217 levels decrease during treatment. The subject may have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia. The method may also include assessing the subject's cognitive function using one or more standardized tests during treatment. AR1001 may be administered in a pharmaceutical composition in the form of a tablet or capsule.

ELASTIN-LIKE POLYPEPTIDES FOR NON-COVALENT CAPTURE OF VESCALAGIN AND ENHANCED PERMEATION THROUGH NASAL MUCOSA

Resumen de: WO2026090369A1

A composition and method of using the composition to treat neurological disorders including Alzheimer's disease are disclosed wherein the composition includes an elastin-like polypeptide (ELP) and a drug. The ELP undergoes a transition from a solution phase to a gel phase as the temperature is raised above a transition temperature, and in doing so sequesters at least a portion of the drug into the gel phase. The composition is configured such that intranasal delivery of the composition results in gelation and sequestration of the drug by the ELP, thereby allowing the drug to traverse olfactory mucosa into brain tissue in order to treat neurological disorders, including Alzheimer's disease.

GENE SEQUENCE CONSTRUCT USED FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES

Resumen de: US20260117234A1

0000 A gene sequence construct used for the treatment of central nervous system diseases: by means of the construction of an auto-processing expression vector, tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), aromatic amino acid dopa decarboxylase (AADC), and so on may be simultaneously expressed; proteins are connected by means of an auto-processing unit (APU); the use of a viral vector to introduce the construct into a target cell may ultimately result in the high-efficiency expression of tyrosine hydroxylase (TH), GTP-cyclohydrolase I (GCH1), aromatic amino acid dopa decarboxylase (AADC), and so on having independent functions, being used in the prevention or treatment of Parkinson's disease, Alzheimer's disease and other neurodegenerative diseases.

METHODS OF TREATING AMYLOID PATHOLOGY

Resumen de: WO2026090552A1

Methods and compositions are provided for treating Alzheimer's disease by administering interleukin-33 (IL-33) to a subject. Methods of gene therapy are also provided for expressing IL-33 in vivo in the brain of a subject in effective amounts sufficient to treat amyloid plaque pathology and reduce numbers of plaques in the brain.

PROTEIN FOR INHIBITING CONSERVED HELIX OF TDP-43 AND USE THEREOF

Resumen de: WO2026086833A1

Disclosed in the present invention are a protein for inhibiting the conserved helix of TDP-43 and the use thereof. The protein contains an amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2. Further disclosed in the present invention are the use of the protein in the preparation of a drug for diagnosing, preventing and/or treating neurodegenerative diseases, and the use in the preparation of an inhibitor of a target protein containing the conserved helix of TDP-43 LCD. In the present invention, by means of using artificial intelligence-assisted protein design techniques, a high-affinity non-natural protein that precisely binds to the conserved helix of a TDP-43 protein is designed, which is used for inhibiting the participation of the conserved helix region in the formation of a β-sheet aggregation core, is mainly used in the treatment of diseases targeting the TDP-43 protein, such as amyotrophic lateral sclerosis, and is used as a research tool for TDP-43 protein phase separation experiments.

METHOD OF TREATING PRECLINICIAL ALZHEIMER'S DISEASE

Resumen de: AU2024367338A1

The application describes a phosphorylated tau targeted active Immunotherapy to treat preclinical Alzheimer's Disease.

METHODS OF USE OF (4R,5R)-5-(2-CHLOROPHENYL)-4-(5-(PHENYLETHYNYL)PYRIDIN-3-YL)OXAZOLIDIN-2-ONE

Resumen de: AU2023468841A1

The present disclosure provides methods of treating Alzheimer's disease and other disorders using (4R,5R)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one (Compound 1).

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

Nº publicación: US20260116878A1 30/04/2026

Solicitante:

BIOSPLICE THERAPEUTICS INC [US]
BioSplice Therapeutics, Inc.

Resumen de: US20260116878A1

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.